Tobacco dependence is prevalent in patients with opioid abuse histories. Cigarette smoking rates in both intreatment and out-of-treatment samples generally range from 80 to 90%. There have been few attempts to treat opioid dependent smokers, and the extant attempts have met with limited success. The proposed study is an attempt to use an innovative motivational system, combined with extended behavioral and pharmacological treatment, to produce sustained abstinence in this population. The intervention is modeled on those used successfully in published and on-going work by our group with other complex smokers. The primary hypothesis is that the Innovative System (IS) will be more effective than the Standard Treatment Control (STC) at 12 and 18 months after entrance into the intervention. Hypotheses concerning individual differences in outcomes are also proposed, and these include both behavioral and pharmacogenetic variables. The data will also provide preliminary information about whether smoking cessation or cessation attempts are correlated with change in use of illicit drugs. Two-hundred buprenorphine treatment patients who smoke more than five cigarettes per day will be randomly assigned to either IS or to STC. Intent to quit smoking is not required as an inclusion criterion. In the STC, participants will receive a brochure on quitting, a list of local referrals, and an information sheet that tells them how to obtain cessation medication through the City of San Francisco public health care system. In the IS, participants will be counseled using a computerized counseling system at baseline and months 3, 6, and 12. The system is designed to increase motivation to quit smoking. At any time after entrance into the study up until month 12, if the participant requests smoking cessation treatment, treatment that uses both combined pharmacotherapy and behavioral counseling will be provided. Pharmacotherapy will consist of nicotine replacement treatment (NRT). If NRT fails to produce abstinence, varenicline will be provided. Treatment is available for six months after it is initiated. Assessment points are at baseline, and months 3, 6, 12, and 18. Seven-day point prevalence abstinence from cigarettes is the primary dependent variable. This study is significant in that it offers an innovative approach for a population with high smoking rates.

Public Health Relevance

This project compares an innovative intervention for tobacco dependence with standard treatment for cigarette smokers who are also being treated for opioid dependence. If successful; this intervention will improve the health of opioid addicted individuals. There is a high rate of smoking in this population; and current treatments have had limited success. Thus; it will contribute to the public health by decreasing the use of a harmful substance?tobacco?in one group of smokers.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009253-20
Application #
8668017
Study Section
Special Emphasis Panel (ZDA1-EXL-T)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
20
Fiscal Year
2014
Total Cost
$358,994
Indirect Cost
$126,635
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Weisner, Constance M; Chi, Felicia W; Lu, Yun et al. (2016) Examination of the Effects of an Intervention Aiming to Link Patients Receiving Addiction Treatment With Health Care: The LINKAGE Clinical Trial. JAMA Psychiatry 73:804-14
Guydish, Joseph; Masson, Carmen; Flentje, Annesa et al. (2016) Scientific writing seminar for early-stage investigators in substance abuse research. Subst Abus 37:238-41
Trager, Evan; Khalili, Mandana; Masson, Carmen L et al. (2016) Hepatitis C Screening Rate Among Underserved Adults With Serious Mental Illness Receiving Care in California Community Mental Health Centers. Am J Public Health 106:740-2
Schuck, Rachel K; Dahl, Audun; Hall, Sharon M et al. (2016) Smokers with serious mental illness and requests for nicotine replacement therapy post-hospitalisation. Tob Control 25:27-32
Guydish, Joseph; Gruber, Valerie A; Le, Thao et al. (2016) A Pilot Study of a Readiness Group to Increase Initiation of Smoking Cessation Services among Women in Residential Addiction Treatment. J Subst Abuse Treat 63:39-45
Guydish, Joseph; Tajima, Barbara; Pramod, Sowmya et al. (2016) Use of multiple tobacco products in a national sample of persons enrolled in addiction treatment. Drug Alcohol Depend 166:93-9
Kalapatapu, Raj K; Delucchi, Kevin L; Wang, Sophia et al. (2016) Substance use history in behavioral-variant frontotemporal dementia versus primary progressive aphasia. J Addict Dis 35:36-41
Barnett, Paul G; Jeffers, Abra; Smith, Mark W et al. (2016) Cost-Effectiveness of Integrating Tobacco Cessation Into Post-Traumatic Stress Disorder Treatment. Nicotine Tob Res 18:267-74
Pagano, Anna; Tajima, Barbara; Guydish, Joseph (2016) Barriers and Facilitators to Tobacco Cessation in a Nationwide Sample of Addiction Treatment Programs. J Subst Abuse Treat 67:22-9
Campbell, Barbara K; Le, Thao; Andrews, K Blakely et al. (2016) Smoking among patients in substance use disorders treatment: associations with tobacco advertising, anti-tobacco messages, and perceived health risks. Am J Drug Alcohol Abuse 42:649-656

Showing the most recent 10 out of 311 publications